International Biotechnology (IBT) Share Price, News & Analysis

Company Overview

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. Investments may also be made in related sectors such as medical devices and healthcare services. While the Company’s portfolio is held as one pool of assets, for operational purposes there is a quoted portfolio and an unquoted portfolio. The portfolio is diversified by geography, industry sub-sector and investment size with no single investment in a company normally accounting for more than 15% of the portfolio at the time of investment. The portfolio is split between large, mid and small-capitalisation companies, primarily quoted on stock exchanges in North America, where the most established and commercial biotech and other life sciences companies and companies operating in related sectors are based, though investments will also be made in Europe, Asia and Australia. Investments may also be made into unquoted companies and into funds not quoted on a stock exchange, including venture capital funds. This may include funds managed by the Investment Manager and/or members of its group. The primary purpose of investment in unquoted funds will be to gain exposure to unquoted companies. The Company may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. Forward or derivative transactions are not used by the Company. The Company may borrow from time to time to exploit specific investment opportunities, rather than to apply long-term structural gearing to the Company’s portfolio of investments.

Key Stats

• Today's Range: 561.45 to 576.32
• 50-Day Range: 480 to 662
• 52-Week Range: 480 to 736
• Volume: 10,268 shs
• Average Volume: 83,414 shs
• Market Capitalization: £201.68 million
• P/E Ratio: 5.36
• Dividend Yield: 5.17%
• Price Target: N/A
• Consensus Rating: N/A

IBT Stock Analysis - Frequently Asked Questions

How have IBT shares performed this year?

International Biotechnology's stock was trading at GBX 682 at the beginning of 2025. Since then, IBT shares have decreased by 17.7% and is now trading at GBX 561.45.
View the best growth stocks for 2025 here.

How were International Biotechnology's earnings last quarter?

International Biotechnology (LON:IBT) released its earnings results on Tuesday, May, 13th. The company reported ($5.60) earnings per share for the quarter. International Biotechnology had a trailing twelve-month return on equity of 13.67% and a net margin of 90.66%.

How do I buy shares of International Biotechnology?

Shares of IBT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of International Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that International Biotechnology investors own include Vanquis Banking Group (PFG), 1724525 (ADN.L) (ADN), abrdn New India Investment Trust (ANII), The Berkeley Group (BKG), GLI Finance (GLIF), Hurricane Energy (HUR) and Oxford Pharmascience Group (OXP).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/28/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Financial Services
• Industry: Asset Management
• Sub-Industry: N/A
• Current Symbol: LON:IBT
• CIK: N/A
• Web: www.ibtplc.com
• Phone: 44 20 7421 7070
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX 104.80
• Trailing P/E Ratio: 5.41
• Forward P/E Ratio: 600.47
• P/E Growth: N/A
• Net Income: £37.91 million
• Net Margins: 90.66%
• Pretax Margin: N/A
• Return on Equity: 13.67%
• Return on Assets: 3.57%

Debt

• Debt-to-Equity Ratio: 8.09
• Current Ratio: N/A
• Quick Ratio: 0.32

Sales & Book Value

• Annual Sales: £41.82 million
• Price / Sales: 4.87
• Cash Flow: GBX 3.64 per share
• Price / Cash Flow: 155.74
• Book Value: GBX 766.24 per share
• Price / Book: 0.74

Miscellaneous

• Outstanding Shares: 35,921,299
• Free Float: N/A
• Market Cap: £203.53 million
• Optionable: Not Optionable
• Beta: 0.21